**Briefing: Nicotine for policymakers**

# Summary and key insights

* Nicotine is the primary psychoactive agent in tobacco and alternative nicotine delivery systems (ANDS - vapes, pouches, heated and smokeless tobacco). It is a stimulant that produces subjective feelings of pleasure, reduces stress and anxiety and improves aspects of cognitive function. Its use can make people feel better and feel as though they function better. Nicotine does not cause drug effects like intoxication, oblivion, hallucinations, or violence. It may also have therapeutic benefits, showing promise for some inflammatory diseases, ADHD, and Parkinson’s Disease, among others.
* The subjectively perceived positive aspects of nicotine use largely explain why people use nicotine. However, these rewards can consolidate into dependence. Over time, withdrawal and craving reinforce nicotine use. While nicotine may provide immediate relief from stress, its overall impact may increase stress levels physiologically and psychologically due to the cycle of use, relief, and withdrawal.
* Nicotine use is disproportionately prevalent in poorer, marginalised or otherwise disadvantaged sub-populations. Nicotine probably interacts with elevated levels of stress in these groups.
* There is no simple answer to the question, *Is nicotine addictiv*e? It depends on the characteristics of the user, the route of administration, and the definition of “addiction”, which is an imprecise and stigmatising term. *Addiction* usually refers to compulsive behaviour *that persists in the face of significant harm caused to the user*. Cigarette smoking meets this definition, but ANDS use may not. It is better to think of nicotine dependence or addiction as an emergent constellation of behaviours with consequences for the individual rather than an intrinsic property of a molecule, device or liquid.
* Nicotine is not a major direct cause of smoking-related disease. Dozens of other hazardous and potentially hazardous chemicals that form through the combustion process and constitute the particles and gases of tobacco smoke are overwhelmingly the causes of smoking-related diseases.
* Nicotine in isolation is much less harmful than smoking but not entirely harmless. It does not cause cancer, heart disease or lung illnesses but may increase risks in people with preexisting tumours or cardiovascular conditions. Smoking causes poor pregnancy outcomes, but nicotine is unlikely to be the primary cause. Nicotine causes peripheral vasoconstriction, which may lead to lowered infant birthweight and peripheral arterial disease in adults.
* Nicotine is the primary reason people use tobacco or ANDS, and the use of these products should be understood as *nicotine-seeking behaviour*. Within broad limits, the user, not the product, determines the dose. Users generally regulate their intake to match a preferred level of nicotine absorption. Regulatory schemes that try to control nicotine intake through restrictions on product design are unlikely to succeed, as users titrate their nicotine intake to preferred levels, resulting in “compensation” (using the product more intensively) or switching nicotine products if compensation is not possible.
* As with other psychoactive substances – alcohol, caffeine, cannabis, etc. - the demand for nicotine is unlikely to disappear even with punitive laws. Demand is driven primarily by the real or perceived benefits experienced by those using it and, for some people, the effort required to stop.
* The main deterrent to nicotine use, the multiple health and welfare harms arising from *smoking*, is significantly reduced in smoke-free alternative nicotine delivery systems. The secondary deterrent is the effect of policies designed to control *smoking*, such as high taxes. For substantially safer alternatives, this deterrent should also significantly diminish. It is possible, therefore, that overall societal nicotine use will increase, though the total harms associated with using nicotine will substantially decline.

# What is nicotine?

**What is nicotine?** Nicotine[[1]](#endnote-1) is a naturally occurring alkaloid present in the tobacco plant, in which it functions as a botanical insecticide. It can also be made synthetically. Nicotine is also present in tea, peppers, tomatoes, potatoes, cauliflower and eggplant,[[2]](#endnote-2) though dietary exposure is far lower than through tobacco use and does not have a noticeable psychoactive effect.[[3]](#endnote-3) Humans have deliberately consumed nicotine, whether through pipes, cigars, chewing, snuffing, or cigarette smoking, for over 12,000 years.[[4]](#endnote-4) At the levels intentionally consumed by tobacco or ANDS users, nicotine is not poisonous. For humans, it functions as a psychoactive substance[[5]](#endnote-5), working as both a stimulant and an anxiolytic (i.e. with calming effects on anxiety). Unlike many drugs of abuse, nicotine does not lead to acute and often harmful effects such as intoxication, violence, oblivion, paranoia, disorientation, loss of control, or hallucinations. However, nicotine use does provide psychoactive reward and reinforcing effects. Tolerance to initial aversive effects in naive users soon develops, which frequently leads to dependence and unpleasant withdrawal symptoms following abstinence.

**How does nicotine work as a drug?** When tobacco is smoked, sucked or chewed, the nicotine is released from the tobacco and enters the blood via the oral cavity, airways, lungs, or nasal passages, then makes its way to the brain via the arterial circulation. Nicotine binds to receptors in the brain to release several neurotransmitters, most notably dopamine[[6]](#endnote-6) and adrenaline.[[7]](#endnote-7) These interactions produce feelings of pleasure,[[8]](#endnote-8) increased alertness,[[9]](#endnote-9) improved cognitive function,[[10]](#endnote-10) [[11]](#endnote-11) and mood regulation, such as reduced stress and anxiety.[[12]](#endnote-12) [[13]](#endnote-13) For example, research conducted through the Intramural Research Program of the U.S. National Institute on Drug Abuse concluded: [[14]](#endnote-14)

*We found significant positive effects of nicotine or smoking on six domains: fine motor, alerting, attention-accuracy and response time (RT), orienting attention-RT, short-term episodic memory-accuracy, and working memory-RT.*

This range of subjectively positive effects is important in explaining why there is *demand* for nicotine – for some people, the use of nicotine can make them feel or function better. That observation should not be understood as an endorsement of nicotine use or a recommendation, but it is an *explanation*. This range of effects also forms the basis of reward and reinforcement that lead some users to experience dependence and adverse withdrawal symptoms when they stop.[[15]](#endnote-15) [[16]](#endnote-16)

**Therapeutic effects of nicotine**. In some circumstances, nicotine can have anti-inflammatory or regulatory effects with potential therapeutic benefits in preventing, treating or relieving the symptoms of certain diseases. These may include Parkinson’s,[[17]](#endnote-17) [[18]](#endnote-18) ulcerative colitis,[[19]](#endnote-19) [[20]](#endnote-20) ADHD,[[21]](#endnote-21) [[22]](#endnote-22) [[23]](#endnote-23) [[24]](#endnote-24) and psychosis.[[25]](#endnote-25) [[26]](#endnote-26) [[27]](#endnote-27) [[28]](#endnote-28) [[29]](#endnote-29) Smokers were significantly less likely to contract COVID-19, suggesting a possible protective effect.[[30]](#endnote-30) [[31]](#endnote-31) However, it is unclear if this was attributable to nicotine, some other component of smoke, or a statistical artefact. Much of the discourse on therapeutic effects has been cautiously expressed because of the justifiable concern that it might encourage smoking, and the research is often suggestive, not conclusive, or has an ambiguous direction of causation. Tobacco and ANDS are not medications and should not be used to treat these conditions as an alternative to medical supervision. However, some people may be subconsciously using nicotine to self-medicate or ease symptoms arising from these conditions. This is an *explanation*, not a recommendation.

**Who uses nicotine?** Tobacco or nicotine use is not uniformly distributed across the whole population at any given age. It is driven by various genetic and psychosocial factors (characteristics of the individual and their family and social circumstances).[[32]](#endnote-32) One study found ninety-eight distinct predictors for smoking onset:[[33]](#endnote-33)

*An increased risk of smoking onset was consistently (i.e., in four or more studies) associated with increased age/grade, lower SES, poor academic performance, sensation seeking or rebelliousness, intention to smoke in the future, receptivity to tobacco promotion efforts, susceptibility to smoking, family members’ smoking, having friends who smoke, and exposure to films.*

Nicotine use is disproportionately prevalent among those experiencing some form of stress, disadvantage, minority status, other forms of marginalisation, or challenging history such as neglect or abuse.[[34]](#endnote-34) [[35]](#endnote-35) [[36]](#endnote-36) [[37]](#endnote-37) [[38]](#endnote-38) [[39]](#endnote-39) [[40]](#endnote-40) The sustained use of nicotine in these populations may be a response to the stress experienced as a result of these disparities.[[41]](#endnote-41) Over time, the brain adapts to nicotine use, requiring higher doses to achieve the same calming effect, which can lead to dependence. Additionally, the withdrawal symptoms associated with nicotine, such as craving, irritability, anxiety, and difficulty concentrating, further contribute to stress when nicotine levels drop in the bloodstream. Thus, while nicotine may provide immediate relief from stress, its overall impact increases stress levels physiologically and psychologically due to the cycle of dependence and withdrawal.

# Nicotine and addiction

**Is nicotine addictive?** Not always. Nicotine addiction is a *behaviour with adverse consequences for the individual* rather than a universal property of the nicotine molecule. Most of what we know about nicotine comes from studies of *smoking* behaviours. In the case of smoking, there is a clear rationale for quitting to avoid significant health and welfare detriments. Yet, many people still struggle to quit, which creates the basis for public health intervention. However, when there is much less harm, the motivation to quit is likely lower, and the consequences of not quitting are less. So, definitions of addiction tend to stress *compulsive and harmful use*, and some care is required in defining terms like addiction (see below). This is why we treat caffeine and our need for morning coffee differently – we may be dependent on it, but it does not do much harm.[[42]](#endnote-42) Whether nicotine is *addictive* depends on the definition used, the characteristics of the user (e.g. genetics, stress or other factors that increase the intensity of use), the user’s pattern of use, and the method of nicotine administration.

**Definitions of addiction**. Whether nicotine is “addictive” also depends, crucially, on the chosen definition of the term “addiction”. This is a loaded, stigmatising word and is often used imprecisely.[[43]](#endnote-43) Most formal definitions of addiction not only require dependent and compulsive use but also serious net harm to the user.[[44]](#endnote-44) For example, the definition of addiction used in the Addiction Ontology is as follows:[[45]](#endnote-45)

*A mental disposition towards repeated episodes of abnormally high levels of motivation to engage in a behaviour, acquired as a result of engaging in the behaviour, where the behaviour results in risk or occurrence of serious net harm.*

The U.S. National Institute of Drug Use (NIDA) also includes adverse consequences within its definition:[[46]](#endnote-46) [[47]](#endnote-47)

*Addiction is a chronic disease characterised by drug seeking and use that is compulsive, or difficult to control, despite harmful consequences.*

The American Psychiatric Association prefers the more clinically precise title substance use disorder (SUD) rather than addiction:[[48]](#endnote-48)

*Substance use disorder (SUD) is a complex condition in which there is uncontrolled use of a substance despite harmful consequence. People with SUD have an intense focus--sometimes called an addiction--on using a certain substance(s) such as alcohol, tobacco, or other psychoactive substances, to the point where their ability to function in day-to-day life becomes impaired.*

**Substance use disorder.** In psychiatry, the term “addiction” has largely been superseded by the more nuanced concept of substance use disorder, which considers different dimensions of harm. The American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) refers to substance use disorder (SUD), including Tobacco Use Disorder.[[49]](#endnote-49) Substance use disorders are assessed against eleven criteria,[[50]](#endnote-50) which cover four broad categories of problem: impaired control, social problems, risky use, and physical dependence. Substance use disorder is graded from mild to severe according to the number of criteria met. Severe substance use disorder, involving six or more criteria, is sometimes seen as a clinical equivalent to the more colloquial term addiction.[[51]](#endnote-51) [[52]](#endnote-52) Nicotine use does not generally cause impaired control or social problems, and its riskiness depends heavily on the type of product used.

**The public health significance of harm**. Unless there is significant harm to the user, their family, bystanders or wider society, the case for a public health intervention to address any form of substance use or compulsive behaviour is greatly diminished. In its definition of “addiction”, the Addiction Ontology provides the following rationale:

*This entity focuses on abnormal motivation to engage in a behaviour and includes serious net harm as a feature. The reason is to limit the class to things that merit a treatment and public health response. It is a quantitative entity and a fuzzy set because there can be varying thresholds set for degree of harm and strength of motivation. As a result, it is essential to operationalise the term for it to be meaningful.*

This insight should drive resources to *smoking cessation* and recognition that “vaping cessation” is unlikely to be a cost-effective use of public or non-profit funds. All healthcare systems ration in some way, and spending the marginal dollar on smoking cessation or other interventions with better cost-effectiveness in terms of health outcomes per dollar spent will always be better.

**Other reinforcers.** Though nicotine is the essential psychoactive agent in cigarette smoke, there are others, including, for example, monoamine oxidase inhibitors (MAOIs) found in smoke. MAOIs inhibit the action of the enzyme monoamine oxidase, which breaks down dopamine and other monoamines such as serotonin, causing them to build up and persist for longer, enhancing the psychoactive effects of nicotine.[[53]](#endnote-53) This may be an important consideration in explaining differences in the dependence-forming potential of different tobacco and nicotine products. Reinforcement is not just chemical; it may be driven by behavioural rituals and triggered by cues[[54]](#endnote-54) [[55]](#endnote-55) or marketing.[[56]](#endnote-56) [[57]](#endnote-57)

**Nicotine and abuse liability – a regulator’s dilemma.** Nicotine use tends to be more strongly reinforcing when the levels of nicotine rise rapidly and peak at a high level in the brain, creating a spike or “bolus”. The transport of nicotine as it is absorbed in the body and carried to the brain is known as *pharmacokinetics*, often abbreviated to “PK”. The PK profile (the speed with which it increases, the peak level reached) is primarily determined by three interacting factors:

1. the route of administration (e.g., via inhalation, absorption in the mouth, or through the skin),
2. characteristics of the product or device (e.g., nicotine concentration, particle size, pH)
3. individual user characteristics (e.g., puffing rate and depth for inhaled products or use time for oral products, which may reflect the strength of their drive to use nicotine).

Abuse liability is a concept used by regulators to address the concern that users could become dependent on a therapeutic product. For nicotine, PK studies are often used to characterise abuse liability. However, this can present a dilemma when assessing consumer-based reduced-risk alternatives to cigarettes, such as vapes or pouches. The PK profile may also reflect their efficacy as cigarette replacements, matching the PK profile experienced as a reward by smokers. Pharmaceutical regulators have generally required manufacturers of nicotine replacement therapies (NRT) to keep abuse liability low, but this has likely made NRT less effective for smoking cessation.[[58]](#endnote-58) [[59]](#endnote-59) [[60]](#endnote-60)

# The challenge of regulating nicotine exposure

**Users control their nicotine exposure, and this may lead to counterintuitive effects**. It is not a surprise that alcohol drinkers control the amount of alcohol they consume, drinking larger volumes of beer and smaller volumes of whiskey for the same alcohol intake. Drinkers can do this by deeper and more frequent gulps of beer and by sipping whiskey. To facilitate this, beer is served in larger glasses and usually without a straw to constrict the flow. There are equivalents for nicotine: users control or “titrate” their nicotine intake by varying their puff depth and frequency (known as “puff topography”) and by their choice of product to facilitate the exposure they want without excessive effort. This creates an effect known as “compensation”, in which users adjust their behaviour in response to changes in the availability of nicotine.[[61]](#endnote-61) [[62]](#endnote-62) For example, reducing nicotine strength may cause a greater intake of vapour aerosol to achieve the same nicotine exposure.

**Attempts to measure and regulate nicotine delivery**. Several ways of characterising and regulating nicotine exposure have been proposed. As discussed below, these may be ineffective and may be misleading or counterproductive.

* **Nicotine yield**. This approach was common until the 2000s when it became no longer possible to ignore its flaws. Nicotine yield is a measure of the nicotine that is emitted from the product during use under standardised smoking regimes using a smoking machine.[[63]](#endnote-63) The nicotine yield is the mass of nicotine trapped on a filter pad, reported in mg per cigarette, typically 0.1-3.0mg per stick.[[64]](#endnote-64) The challenge is that people adjust their smoking behaviour (“compensation”) to obtain the nicotine they want (“titration”),[[65]](#endnote-65) [[66]](#endnote-66) and this varies greatly between individuals and by race,[[67]](#endnote-67) genetics,[[68]](#endnote-68) and deprivation.[[69]](#endnote-69) Further, tobacco companies designed cigarettes that would show low tar and nicotine yields on machines but made it easy for users to compensate, for example, by including filter ventilation holes that the user could easily block. This led to falsely reassuring “light” and “mild” brands, which exploited smokers’ concerns about health without doing anything to reduce risk.[[70]](#endnote-70) [[71]](#endnote-71)
* **Nicotine content in tobacco**. There are proposals to control the addictiveness of cigarettes or tobacco by limiting the concentration of nicotine present in the tobacco itself.[[72]](#endnote-72) [[73]](#endnote-73) Denicotinisation is feasible and can be achieved through genetic modification or by chemically lowering the nicotine to a “sub-addictive” level or levels that are too low for compensation to work. The primary health question is how users will respond to mandated low-nicotine standards: will they quit smoking, smoke very low-nicotine cigarettes, switch to safer nicotine products, access illicit nicotine cigarettes, or find workarounds? Removing most of the nicotine from cigarettes approximates to a ban on cigarettes, as most people use them. A *de facto* ban would present a wide range of challenges that regulators and lawmakers must consider carefully. These include public acceptability, especially among those affected, farming and supply chain disruption, enforcement, corruption and community effects, illicit trade and tax revenues.
* **Nicotine strength of e-liquids**. The European Union sets a maximum nicotine concentration for e-liquids of 20mg/ml (about 2% by volume),[[74]](#endnote-74) and this regulatory approach has been used in other jurisdictions.[[75]](#endnote-75) The issue is both acceptability to consumers and user compensation; people consume larger volumes of weaker liquids to achieve their preferred nicotine dose. However, that may increase exposure to contaminants and toxic products of thermal decomposition, but without doing much to change their nicotine exposure [[76]](#endnote-76) [[77]](#endnote-77)
* **Nicotine flux.** This measures the flow rate of nicotine emitted from a product (e.g., micrograms of nicotine per second of puffing).[[78]](#endnote-78) [[79]](#endnote-79) While intended as a proxy for nicotine delivery, parameters defining nicotine flux do not capture all factors that account for nicotine delivery to the user. The main challenge is that the *user* controls this flow by varying the puff frequency, depth and length. Proponents of this method propose to limit the effect of user behaviour by making ENDS devices function as metered-dose products, delivering a fixed or limited dose of nicotine.[[80]](#endnote-80) However, this should be seen as an admission that the idea is unworkable. If that dose is too low or the use of the product is frustrating or unsatisfying, users will seek alternatives, including cigarettes or vaping products that can provide the nicotine dose the user wants.
* **Nicotine “abuse liability”.**This would involve placing limits on pharmacokinetics (PK) or the spike (“bolus”) of nicotine exposure in the brain–the peak level “Cmax” and time to reach the peak “Tmax” or the ratio Cmax/Tmax.[[81]](#endnote-81) Again, these are mainly under the user’s control, though they can be subject to device constraints. For low-risk products, there is ambiguity about the regulatory purpose. Should it be to reduce abuse liability to stop the products from forming dependence, or should it be to match the PK of cigarettes and thereby provide a “satisfying” and viable, low-risk alternative to smoking that works for people who smoke?

The overarching point is that trying to control nicotine use by limiting the devices or liquids through which it is consumed is likely to fail. Users will ultimately access the nicotine they want. It would be like trying to control alcohol use by limiting the size of wine glasses or making people drink through a straw.

# Health effects of nicotine

**Health effects of nicotine**. It is now commonplace to cite Michael Russell’s 1976 insight, “*People smoke for the nicotine but die from the tar*”,[[82]](#endnote-82) to convey the idea that it is not the nicotine that is the primary direct cause of disease and death arising from smoking. It is the reason people smoke and, as a result, expose themselves to thousands of toxicants in cigarette smoke. That insight still holds true today. U.S. Food and Drug Administration leadership reiterated this point in 2017, setting out a strategic approach to nicotine:[[83]](#endnote-83)

*Nicotine, though not benign, is not directly responsible for the tobacco-caused cancer, lung disease, and heart disease that kill hundreds of thousands of Americans each year.*

But if nicotine itself is not directly responsible for the major smoking-related diseases, what are the residual risks? Epidemiological studies of smokeless tobacco[[84]](#endnote-84) [[85]](#endnote-85) [[86]](#endnote-86) [[87]](#endnote-87) or long-term use of nicotine replacement therapy (pharmaceutical nicotine)[[88]](#endnote-88) [[89]](#endnote-89) suggest that serious disease risks *attributable to nicotine* are low or arise in limited circumstances when nicotine consumption is decoupled from smoke inhalation.

* **All-cause mortality**. Long-running surveys of American exclusive smokeless tobacco (SLT) users do not show elevated mortality risks: “*SLT users, in general, did not display a significantly increased risk for all-cause mortality, all-cancer mortality, or diseases of the heart compared to never-tobacco users […] Additionally, SLT use had no discernible adverse effect on any of the nine leading causes of death and did not increase mortality risk for any of the major neoplasms often associated with SLT use*”.[[90]](#endnote-90)
* **Cardiovascular disease**, there is no generalised cardiovascular risk attributable to nicotine, but there may be a nicotine-specific risk to people with preexisting cardiovascular conditions:[[91]](#endnote-91)

“*the risks of nicotine without tobacco combustion products (cigarette smoke) are low compared to cigarette smoking but are still of concern in people with cardiovascular disease*.

Studies of nicotine use without smoke exposure, for example, snus use, do not show elevated cardiovascular risk, and that “*toxic components other than nicotine appear implicated in the pathophysiology of smoking-related ischemic heart disease*”[[92]](#endnote-92) and “*use of snus was not associated with the risk of stroke. Hence, nicotine is unlikely to contribute importantly to the pathophysiology of stroke*.”[[93]](#endnote-93)

* **Cancer.** The U.S. Surgeon General’s Report of 2014 concluded: [[94]](#endnote-94)

*“The evidence is inadequate to infer the presence or absence of a causal relationship between exposure to nicotine and risk for cancer.”*

However, this report notes animal studies showing nicotine “*is a tumor promoter in some experimental models*” but cites human epidemiological data suggesting “*that in humans nicotine may not have a strong tumor-promoting effect*”. To the extent that smokeless tobacco poses any cancer risk, evidence suggests this is caused by exposure to compounds other than nicotine.[[95]](#endnote-95) [[96]](#endnote-96)

* **Respiratory disease**. The evidence does not support a link between systemic nicotine exposure and respiratory disease. Though there is no conclusive evidence, it is possible that direct exposure of lung cells to nicotine[[97]](#endnote-97) or exposure to hazardous agents other than nicotine in an inhaled nicotine aerosol could create respiratory risk.
* **Pregnancy**. Smoking is clearly associated with a range of poor birth outcomes.[[98]](#endnote-98) However, much of this is likely due to exposure to toxicants other than nicotine present in tobacco smoke. The U.S. Surgeon General concluded:[[99]](#endnote-99)

“*Evidence from studies of gene-environment interactions support the hypothesis that components of tobacco other than nicotine may contribute to tobacco-related adverse pregnancy outcomes*.”

A trial of over 1,000 pregnant women who smoked found “*Regular use of e-cigarettes or nicotine patches by pregnant smokers does not appear to be associated with any adverse outcomes*.”[[100]](#endnote-100) While most studies find no risk from vaping, the evidence can be of poor quality and contradictory.[[101]](#endnote-101)

* **Impacts on the adolescent brain**. There has been a high level of political, media and public concern about the effects of nicotine on the developing brain. The U.S. Surgeon General raised this as a significant finding in the 2016 report, *E-Cigarette Use Among Youth and Young Adults*.[[102]](#endnote-102) However, the underlying evidence base is weak, based on animal models or subject to potential confounding of genetic and socioeconomic factors, the influence of other substance abuse, and the role of preexisting neuropsychiatric problems associated with youth smoking.[[103]](#endnote-103) If there were noticeable impairments associated with adolescent nicotine use, these would be observable in the generations of adults who smoked as teenagers. However, there is no compelling evidence to support this: one study found that “*Past smoking was not associated with significantly poorer performance than never smokers in any cognitive domain.*”[[104]](#endnote-104) Recent evidence suggests a further challenge to this argument: there are signs that differences in brain structure may *predate* and *predict* subsequent substance use initiation,[[105]](#endnote-105) with exposure to environmental pollution as a possible underlying cause.[[106]](#endnote-106)
* **Mental health**. There are significantly higher rates of nicotine use in populations with mental health disorders such as ADHD, anxiety disorders, and depression. It is plausible that nicotine use among affected populations is an attempt, consciously or subconsciously, to self-medicate or regulate these disorders.[[107]](#endnote-107) [[108]](#endnote-108) It is also possible that nicotine use could cause or intensify these disorders or that the causal relationship is bidirectional.[[109]](#endnote-109) [[110]](#endnote-110) It is inherently challenging to isolate the direction of any causal relationship in the association, and the evidence is currently contradictory and uncertain. [[111]](#endnote-111) [[112]](#endnote-112)

**Public and professional perceptions of nicotine risks are grossly inaccurate**. There is an extensive body of literature that supports the analysis that “People smoke for the nicotine but die from the tar” or its many variants. Yet, awareness of the basic risk concepts about nicotine is very poor. For example, in the United States, a 2022 study found that 61.2% of smokers believe nicotine causes cancer or don’t know; the authors called for corrective messaging.[[113]](#endnote-113) In New Zealand, proposals to lower the nicotine content of cigarettes were incorrectly understood as making the products safer.[[114]](#endnote-114) In the UK in 2021, only 11% of smokers recognised that ‘none’ or ‘a very small amount’ of the health risks from smoking come from nicotine in tobacco cigarettes.[[115]](#endnote-115) Several surveys show that medical professionals also share these misperceptions. For example, a 2021 U.S. **study** found:[[116]](#endnote-116)

*Overall, the majority of physicians “strongly agreed” that nicotine directly contributes to the development of cardiovascular disease (83.2%), COPD (80.9%), and cancer (80.5%).*

These nicotine misperceptions also underpin misperceptions of the risk of vaping and other smoke-free nicotine options, and this creates a barrier to switching from smoking to smoke-free. The problem is that false perceptions of harm influence behaviour and inhibit beneficial behaviour change, intent, and action.

# Conclusion

When used as intended, nicotine is a relatively benign psychoactive substance and does not cause overdose, intoxication, hallucinations, oblivion or other more extreme drug effects. People use nicotine because it makes them feel better and feel as though they function better, and this underpins the demand for the drug. Nicotine itself does not cause the vast majority of tobacco-related harms, though it does have some adverse health effects and risks. Nicotine use may create dependence by reinforcement through positive rewards and adverse effects of temporary withdrawal and craving. Nicotine can be challenging to quit. We may consider nicotine dependence to be an addiction if the user cannot stop *despite significant harm*, for example, through continued smoking.

For the past 100 years, nicotine has been primarily consumed by inhaling toxic tobacco smoke. However, that is changing as the world begins a transition to nicotine without smoke (vapes, pouches, heated and smokeless tobacco). This opens up a range of policy challenges and opportunities. These products can meet the nicotine demand with significantly reduced harm compared to combustible tobacco. But that also means the loss of the main deterrent to nicotine use: the harms caused by smoking. The emergence of nicotine as a relatively benign drug without major harms associated with its use demands a profound re-evaluation of the position of nicotine as a legal substance (like caffeine, alcohol and, increasingly, cannabinoids) in society.

Regulation of nicotine use is challenging because users largely control their own intake by changing behaviour, changing products, and ultimately seeking illicit supplies of the products they want. Policymakers should accept that the demand for nicotine is inevitable and likely to persist indefinitely. In that case, the policy challenge is to make nicotine available in regulated markets, with lawful suppliers meeting adult demand with safeguards to raise awareness, control marketing and branding, and limit access.

# References

1. National Library of Medicine (US), PubChem. *Nicotine* C10H14N2. <https://pubchem.ncbi.nlm.nih.gov/compound/89594> [↑](#endnote-ref-1)
2. Siegmund, B., Leitner, E., & Pfannhauser, W. (1999). Determination of the nicotine content of various edible nightshades (Solanaceae) and their products and estimation of the associated dietary nicotine intake. *Journal of Agricultural and Food Chemistry*, *47*(8), 3113–3120. <https://doi.org/10.1021/jf990089w> [↑](#endnote-ref-2)
3. Benowitz, N. L., & Jacob, P. (1984). Daily intake of nicotine during cigarette smoking. *Clinical Pharmacology and Therapeutics*, *35*(4), 499–504. [[link](https://doi.org/10.1038/clpt.1984.67)]. Smokers average 37.6mg/day nicotine intake, but dietary intake typically 2.25µg/day (Sigmund et al. op cit) suggesting an approximately 17,000-fold difference. [↑](#endnote-ref-3)
4. Duke, D., Wohlgemuth, E., Adams, K. R., Armstrong-Ingram, A., Rice, S. K., & Young, D. C. (2022). Earliest evidence for human use of tobacco in the Pleistocene Americas. *Nature Human Behaviour*, *6*(2), 183–192. <https://doi.org/10.1038/s41562-021-01202-9> [↑](#endnote-ref-4)
5. National Cancer Institute. *Definition of psychoactive substance*  (2011, February 2) [[link](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/psychoactive-substance)] [↑](#endnote-ref-5)
6. Balfour, D. J. K. (2004). The neurobiology of tobacco dependence: A preclinical perspective on the role of the dopamine projections to the nucleus. *Nicotine & Tobacco Research*, *6*(6), 899–912. <https://doi.org/10.1080/14622200412331324965> [↑](#endnote-ref-6)
7. National Institute on Drug Abuse (US). *How does tobacco deliver its effects?* <https://nida.nih.gov/publications/research-reports/tobacco-nicotine-e-cigarettes/how-does-tobacco-deliver-its-effects> [↑](#endnote-ref-7)
8. Benowitz, N. L. (2008). Neurobiology of nicotine addiction: Implications for smoking cessation treatment. *The American Journal of Medicine*, *121*(4 Suppl 1), S3-10. <https://doi.org/10.1016/j.amjmed.2008.01.015> [↑](#endnote-ref-8)
9. Beer, A. L. (2016). Chapter 27 - Nicotine and Cognition: Effects of Nicotine on Attention and Memory Systems in Humans. In V. R. Preedy (Ed.), *Neuropathology of Drug Addictions and Substance Misuse* (pp. 282–290). Academic Press. [[link](https://doi.org/10.1016/B978-0-12-800213-1.00027-4)] [↑](#endnote-ref-9)
10. Valentine, G., & Sofuoglu, M. (2018). Cognitive Effects of Nicotine: Recent Progress. *Current Neuropharmacology*, *16*(4), 403–414. [[link](https://doi.org/10.2174/1570159X15666171103152136)] [↑](#endnote-ref-10)
11. Alhowail, A. (2021). Molecular insights into the benefits of nicotine on memory and cognition (Review). *Molecular Medicine Reports*, *23*(6), 1–6. <https://doi.org/10.3892/mmr.2021.12037> [↑](#endnote-ref-11)
12. Choi, D., Ota, S., & Watanuki, S. (2015). Does cigarette smoking relieve stress? Evidence from the event-related potential (ERP). *International Journal of Psychophysiology*, *98*(3, Part 1), 470–476. <https://doi.org/10.1016/j.ijpsycho.2015.10.005> [↑](#endnote-ref-12)
13. Kutlu, M. G., & Gould, T. J. (2015). Nicotine Modulation of Fear Memories and Anxiety: Implications for Learning and Anxiety Disorders. *Biochemical Pharmacology*, *97*(4), 498–511. <https://doi.org/10.1016/j.bcp.2015.07.029> [↑](#endnote-ref-13)
14. Heishman, S. J., Kleykamp, B. A., & Singleton, E. G. (2010). Meta-analysis of the acute effects of nicotine and smoking on human performance. *Psychopharmacology*, *210*(4), 453–469. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151730/> [↑](#endnote-ref-14)
15. Benowitz, N. L. (2009). Pharmacology of Nicotine: Addiction, Smoking-Induced Disease, and Therapeutics. *Annual Review of Pharmacology and Toxicology*, *49*, 57. [[link](https://doi.org/10.1146/ANNUREV.PHARMTOX.48.113006.094742)] [↑](#endnote-ref-15)
16. Benowitz, N. L. (2010). Nicotine Addiction. *The New England Journal of Medicine*, *362*(24), 2295–2303. [[link](https://doi.org/10.1056/NEJMra0809890)][[NCBI](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928221/)] [↑](#endnote-ref-16)
17. Mappin-Kasirer, B., Pan, H., Lewington, S., Kizza, J., Gray, R., Clarke, R., & Peto, R. (2020). Tobacco smoking and the risk of Parkinson disease. *Neurology*, 10.1212/WNL.0000000000009437. <https://doi.org/10.1212/WNL.0000000000009437> [↑](#endnote-ref-17)
18. Yang, F., Pedersen, N. L., Ye, W., Liu, Z., Norberg, M., Forsgren, L., Trolle Lagerros, Y., Bellocco, R., Alfredsson, L., Knutsson, A., Jansson, J.-H., Wennberg, P., Galanti, M. R., Lager, A. C., Araghi, M., Lundberg, M., Magnusson, C., & Wirdefeldt, K. (2017). Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease. *International Journal of Epidemiology*, *46*(3), 872–880. <https://doi.org/10.1093/ije/dyw294> [↑](#endnote-ref-18)
19. Zhang, W., Lin, H., Zou, M., Yuan, Q., Huang, Z., Pan, X., & Zhang, W. (2022). Nicotine in Inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. *Frontiers in Immunology*, *13*. <https://doi.org/10.3389/fimmu.2022.826889> [↑](#endnote-ref-19)
20. Kastratovic, N., Markovic, V., Arsenijevic, A., Volarevic, A., Zdravkovic, N., Zdravkovic, M., Brankovic, M., Gmizic, T., Harrell, C. R., Jakovljevic, V., Djonov, V., & Volarevic, V. (2024). The effects of combustible cigarettes and electronic nicotine delivery systems on immune cell-driven inflammation and mucosal healing in ulcerative colitis. *Nicotine & Tobacco Research*, ntae193. <https://doi.org/10.1093/ntr/ntae193> [↑](#endnote-ref-20)
21. van Amsterdam, J., van der Velde, B., Schulte, M., & van den Brink, W. (2018). Causal Factors of Increased Smoking in ADHD: A Systematic Review. *Substance Use & Misuse*, *53*(3), 432–445. <https://doi.org/10.1080/10826084.2017.1334066> [↑](#endnote-ref-21)
22. Liebrenz, M., Frei, A., Fisher, C. E., Gamma, A., Buadze, A., & Eich, D. (2014). Adult attention-deficit/hyperactivity disorder and nicotine use: A qualitative study of patient perceptions. *BMC Psychiatry*, *14*(1), 141. <https://doi.org/10.1186/1471-244X-14-141> [↑](#endnote-ref-22)
23. Potter, A. S., & Newhouse, P. A. (2008). Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. *Pharmacology Biochemistry and Behavior*, *88*(4), 407–417. <https://doi.org/10.1016/j.pbb.2007.09.014> [↑](#endnote-ref-23)
24. Shytle, R. D., Silver, A. A., Wilkinson, B. J., & Sanberg, P. R. (2002). A Pilot Controlled Trial of Transdermal Nicotine in the Treatment of Attention Deficit Hyperactivity Disorder. *The World Journal of Biological Psychiatry*. <https://doi.org/10.3109/15622970209150616> [↑](#endnote-ref-24)
25. Waterhouse, U., Brennan, K. A., & Ellenbroek, B. A. (2018). Nicotine self-administration reverses cognitive deficits in a rat model for schizophrenia. *Addiction Biology*, *23*(2), 620–630. <https://doi.org/10.1111/adb.12517> [↑](#endnote-ref-25)
26. Morisano, D., Wing, V. C., Sacco, K. A., Arenovich, T., & George, T. P. (2013). Effects of Tobacco Smoking on Neuropsychological Function in Schizophrenia in Comparison to Other Psychiatric Disorders and Non-psychiatric Controls. *The American Journal on Addictions*, *22*(1), 46–53. <https://doi.org/10.1111/j.1521-0391.2013.00313.x> [↑](#endnote-ref-26)
27. Sacco, K. A., Termine, A., Seyal, A., Dudas, M. M., Vessicchio, J. C., Krishnan-Sarin, S., Jatlow, P. I., Wexler, B. E., & George, T. P. (2005). Effects of Cigarette Smoking on Spatial Working Memory and Attentional Deficits in Schizophrenia: Involvement of Nicotinic Receptor Mechanisms. *Archives of General Psychiatry*, *62*(6), 649–659. <https://doi.org/10.1001/archpsyc.62.6.649> [↑](#endnote-ref-27)
28. Featherstone, R. E., & Siegel, S. J. (2015). Chapter Two—The Role of Nicotine in Schizophrenia. In M. De Biasi (Ed.), *International Review of Neurobiology* (Vol. 124, pp. 23–78). Academic Press. <https://doi.org/10.1016/bs.irn.2015.07.002> [↑](#endnote-ref-28)
29. Featherstone, R. E., & Siegel, S. J. (2015). Chapter Two—The Role of Nicotine in Schizophrenia. In M. De Biasi (Ed.), International Review of Neurobiology (Vol. 124, pp. 23–78). Academic Press. <https://doi.org/10.1016/bs.irn.2015.07.002> [↑](#endnote-ref-29)
30. Simons, D., Shahab, L., Brown, J., & Perski, O. (2021). The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review with Bayesian meta-analyses (version 12). *Qeios*. <https://doi.org/10.32388/UJR2AW.15> [↑](#endnote-ref-30)
31. Farsalinos, K., Niaura, R., Le Houezec, J., Barbouni, A., Tsatsakis, A., Kouretas, D., Vantarakis, A., & Poulas, K. (2020). Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. *Toxicology Reports*, *7*, 658–663. <https://doi.org/10.1016/j.toxrep.2020.04.012> [↑](#endnote-ref-31)
32. Tyas, S., & Pederson, L. (1998). Psychosocial factors related to adolescent smoking: A critical review of the literature. *Tobacco Control*, *7*(4), 409–420. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1751465/> [↑](#endnote-ref-32)
33. Wellman, R. J., Dugas, E. N., Dutczak, H., O’Loughlin, E. K., Datta, G. D., Lauzon, B., & O’Loughlin, J. (2016). Predictors of the Onset of Cigarette Smoking: A Systematic Review of Longitudinal Population-Based Studies in Youth. *American Journal of Preventive Medicine*, *51*(5), 767–778. <https://doi.org/10.1016/j.amepre.2016.04.003> [↑](#endnote-ref-33)
34. Siddiqi, K., Jawad, M., Mushtaq, N., Ali, S., & Khan, J. A. (2015). Tobacco and Health Disparities. *BioMed Research International*, *2015*(1), 570173. <https://doi.org/10.1155/2015/570173> [↑](#endnote-ref-34)
35. Leventhal, A. M., Bello, M. S., Galstyan, E., Higgins, S. T., & Barrington-Trimis, J. L. (2019). Association of Cumulative Socioeconomic and Health-Related Disadvantage With Disparities in Smoking Prevalence in the United States, 2008 to 2017. *JAMA Internal Medicine*, *179*(6), 777–785. <https://doi.org/10.1001/jamainternmed.2019.0192> [↑](#endnote-ref-35)
36. Kastaun, S., Brose, L. S., Scholz, E., Viechtbauer, W., & Kotz, D. (2022). Mental Health Symptoms and Associations with Tobacco Smoking, Dependence, Motivation, and Attempts to Quit: Findings from a Population Survey in Germany (DEBRA Study). *European Addiction Research*, *28*(4), 287–296. <https://doi.org/10.1159/000523973> [↑](#endnote-ref-36)
37. Glasser, A. M., Hinton, A., Wermert, A., Macisco, J., & Nemeth, J. M. (2022). Characterizing tobacco and marijuana use among youth combustible tobacco users experiencing homelessness – considering product type, brand, flavor, frequency, and higher-risk use patterns and predictors. *BMC Public Health*, *22*(1), 820. <https://doi.org/10.1186/s12889-022-13244-3> [↑](#endnote-ref-37)
38. Ganz, O., Schulz, J. A., Ehlke, S. J., King Jensen, J. L., & Villanti, A. C. (2024). Cigarette smoking behaviors and nicotine dependence at the intersection of sexual identity and sex in the United States: Findings from the National Survey on Drug Use and Health. *Preventive Medicine Reports*, *38*, 102593. <https://doi.org/10.1016/j.pmedr.2024.102593> [↑](#endnote-ref-38)
39. Arrazola, R. A. (2023). US Cigarette Smoking Disparities by Race and Ethnicity—Keep Going and Going! *Preventing Chronic Disease*, *20*. <https://doi.org/10.5888/pcd20.220375> [↑](#endnote-ref-39)
40. Hiscock, R., Bauld, L., Amos, A., Fidler, J. A., & Munafò, M. (2012). Socioeconomic status and smoking: A review. *Annals of the New York Academy of Sciences*, *1248*(1), 107–123. <https://doi.org/10.1111/j.1749-6632.2011.06202.x> [↑](#endnote-ref-40)
41. Koob, G. F., Buck, C. L., Cohen, A., Edwards, S., Park, P. E., Schlosburg, J. E., Schmeichel, B., Vendruscolo, L. F., Wade, C. L., Whitfield, T. W., & George, O. (2014). Addiction as a Stress Surfeit Disorder. *Neuropharmacology*, *76*(0 0), 10.1016/j.neuropharm.2013.05.024. <https://doi.org/10.1016/j.neuropharm.2013.05.024> [↑](#endnote-ref-41)
42. Fagerstrom, K. (2018). A Comparison of Dependence across Different Types of Nicotine Containing Products and Coffee. *International Journal of Environmental Research and Public Health*, *15*(8). <https://doi.org/10.3390/IJERPH15081609> [↑](#endnote-ref-42)
43. National Institute on Drug Abuse (NIDA). (2021). *Words Matter: Preferred Language for Talking About Addiction*. <https://nida.nih.gov/research-topics/addiction-science/words-matter-preferred-language-talking-about-addiction> [↑](#endnote-ref-43)
44. West, R., Cox, S., Notley, C. J., Plessis, G. D., & Hastings, J. (n.d.). *Achieving consensus, coherence, clarity and consistency when talking about addiction*. <https://doi.org/10.1111/add.16393> [↑](#endnote-ref-44)
45. AddictO Vocab. *Addiction*. Accessed 10 September 2024, from <https://addictovocab.org/ADDICTO:0000349> [↑](#endnote-ref-45)
46. National Institute on Drug Abuse (NIDA). Drug Misuse and Addiction, *What is drug addiction?* <https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/drug-misuse-addiction> [↑](#endnote-ref-46)
47. National Institute on Drug Abuse (NIDA). *Understanding Drug Use and Addiction DrugFacts*, accessed 10 September 2024. <https://nida.nih.gov/publications/drugfacts/understanding-drug-use-addiction> [↑](#endnote-ref-47)
48. American Psychiatric Association.. *Addiction and Substance Use Disorders*. Retrieved 11 September 2024, from <https://www.psychiatry.org:443/patients-families/addiction-substance-use-disorders> [↑](#endnote-ref-48)
49. *Diagnostic and Statistical Manual of Mental Disorders | Psychiatry Online*. (2023.). DSM Library. Retrieved 10 September 2024, from <https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425787> [↑](#endnote-ref-49)
50. Hasin, D. S., O’Brien, C. P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W. M., Crowley, T., Ling, W., Petry, N. M., Schuckit, M., & Grant, B. F. (2013). DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. *The American Journal of Psychiatry*, *170*(8), 834–851. <https://doi.org/10.1176/appi.ajp.2013.12060782> [↑](#endnote-ref-50)
51. Gateway Foundation, G. (2021, June 15). *DSM-5 Criteria for Substance Use Disorders*. <https://www.gatewayfoundation.org/addiction-blog/dsm-5-substance-use-disorder/> [↑](#endnote-ref-51)
52. Addiction Policy Forum. (2020, August 17). *DSM-5 Criteria for Addiction Simplified*. <https://www.addictionpolicy.org/post/dsm-5-facts-and-figures> [↑](#endnote-ref-52)
53. Hong, S. W., et al. (2022). Biologically Active Compounds Present in Tobacco Smoke: Potential Interactions Between Smoking and Mental Health. *Frontiers in Neuroscience*, *16*. <https://doi.org/10.3389/fnins.2022.885489> [↑](#endnote-ref-53)
54. Shiffman, S., Dunbar, M., Kirchner, T., Li, X., Tindle, H., Anderson, S., & Scholl, S. (2013). Smoker reactivity to cues: Effects on craving and on smoking behavior. *Journal of Abnormal Psychology*, *122*(1), 264–280. <https://doi.org/10.1037/a0028339> [↑](#endnote-ref-54)
55. Chiamulera, C. (2005). Cue reactivity in nicotine and tobacco dependence: A “multiple-action” model of nicotine as a primary reinforcement and as an enhancer of the effects of smoking-associated stimuli. *Brain Research Reviews*, *48*(1), 74–97. <https://doi.org/10.1016/j.brainresrev.2004.08.005> [↑](#endnote-ref-55)
56. Saad, C., Cheng, B. (Hsu-C., Takamizawa, R., Thakur, A., Lee, C.-W., Leung, L., Veerman, J. L., & Aminde, L. N. (2025). Effectiveness of tobacco advertising, promotion and sponsorship bans on smoking prevalence, initiation and cessation: A systematic review and meta-analysis. *Tobacco Control*. <https://doi.org/10.1136/tc-2024-058903> [↑](#endnote-ref-56)
57. Lovato, C., Watts, A., & Stead, L. F. (n.d.). Impact of tobacco advertising and promotion on increasing adolescent smoking behaviours—Lovato, C - 2011 | Cochrane Library. Retrieved 11 May 2025, from <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003439.pub2/full> [↑](#endnote-ref-57)
58. Le Houezec, J. (2003). Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: A review. *The International Journal of Tuberculosis and Lung Disease*, *7*(9), 811–819. <https://www.ingentaconnect.com/content/iuatld/ijtld/2003/00000007/00000009/art00002> [↑](#endnote-ref-58)
59. Schneider, N. G., Olmstead, R. E., Franzon, M. A., & Lunell, E. (2001). The Nicotine Inhaler. *Clinical Pharmacokinetics*, *40*(9), 661–684. <https://doi.org/10.2165/00003088-200140090-00003> [↑](#endnote-ref-59)
60. Azzopardi, D., Ebajemito, J., McEwan, M., Camacho, O. M., Thissen, J., Hardie, G., Voisine, R., Mullard, G., Cohen, Z., & Murphy, J. (2022). A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products. *Scientific Reports*, *12*(1), 6949. <https://doi.org/10.1038/s41598-022-10544-x> [↑](#endnote-ref-60)
61. Ashton, H., Stepney, R., & Thompson, J. W. (1979). Self-titration by cigarette smokers. *British Medical Journal*, *2*(6186), 357–360. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1596095/> [↑](#endnote-ref-61)
62. Soar, K., Kimber, C., McRobbie, H., & Dawkins, L. E. (2019). Nicotine absorption from e-cigarettes over 12 months. *Addictive Behaviors*, *91*, 102–105. <https://doi.org/10.1016/j.addbeh.2018.07.019> [↑](#endnote-ref-62)
63. International Standards Organisation. (2021, June). ISO 10315:2021 Cigarettes—Determination of nicotine in total particulate matter from the mainstream smoke—Gas-chromatographic method. ISO. <https://www.iso.org/standard/79002.html> [↑](#endnote-ref-63)
64. Kuiper, N., Coats, E. M., Crawford, T. N., Gammon, D. G., Loomis, B., Watson, C. H., Melstrom, P. C., Lavinghouze, R., Rogers, T., & King, B. A. (2020). Trends in Manufacturer-Reported Nicotine Yields in Cigarettes Sold in the United States, 2013–2016. *Preventing Chronic Disease*, *17*, E148. <https://doi.org/10.5888/pcd17.200205> [↑](#endnote-ref-64)
65. Jarvis, M. J., Boreham, R., Primatesta, P., Feyerabend, C., & Bryant, A. (2001). Nicotine Yield From Machine-Smoked Cigarettes and Nicotine Intakes in Smokers: Evidence From a Representative Population Survey. *JNCI: Journal of the National Cancer Institute*, *93*(2), 134–138. <https://doi.org/10.1093/jnci/93.2.134> [↑](#endnote-ref-65)
66. Maron, D. J., & Fortmann, S. P. (1987). Nicotine yield and measures of cigarette smoke exposure in a large population: Are lower-yield cigarettes safer? *American Journal of Public Health*, *77*(5), 546–549. <https://doi.org/10.2105/ajph.77.5.546> [↑](#endnote-ref-66)
67. MacKillop, J., Obasi, E., Amlung, M. T., McGeary, J. E., & Knopik, V. S. (2010). The Role of Genetics in Nicotine Dependence: Mapping the Pathways from Genome to Syndrome. *Current Cardiovascular Risk Reports*, *4*(6), 446–453. <https://doi.org/10.1007/s12170-010-0132-6> [↑](#endnote-ref-67)
68. St Helen, G., Dempsey, D., Wilson, M., Jacob, P., & Benowitz, N. L. (2013). Racial differences in the relationship between tobacco dependence and nicotine and carcinogen exposure. *Addiction (Abingdon, England)*, *108*(3), 607–617. <https://doi.org/10.1111/j.1360-0443.2012.04077.x> [↑](#endnote-ref-68)
69. Pan, C., Qi, X., Cheng, S., Chen, Y., Li, C., Zhang, H., Zhang, J., Zhang, Z., Yang, X., Meng, P., Yao, Y., Wen, Y., Jia, Y., & Zhang, F. (2024). The Comprehensive Effect of Socioeconomic Deprivation on Smoking Behavior: An Observational and Genome-Wide by Environment Interaction Analyses in UK Biobank. *International Journal of Mental Health and Addiction*, *22*(1), 344–360. <https://doi.org/10.1007/s11469-022-00876-0> [↑](#endnote-ref-69)
70. Mutti, S., Hammond, D., Borland, R., Cummings, K. M., O’Connor, R. J., & Fong, G. T. (2011). Beyond Light & Mild: Cigarette Brand Descriptors and Perceptions of Risk in the International Tobacco Control (ITC) Four Country Survey. *Addiction (Abingdon, England)*, *106*(6), 1166–1175. <https://doi.org/10.1111/j.1360-0443.2011.03402.x> [↑](#endnote-ref-70)
71. Mutti, S., Hammond, D., Borland, R., Cummings, K. M., O’Connor, R. J., & Fong, G. T. (2011). Beyond Light & Mild: Cigarette Brand Descriptors and Perceptions of Risk in the International Tobacco Control (ITC) Four Country Survey. *Addiction (Abingdon, England)*, *106*(6), 1166–1175. <https://doi.org/10.1111/j.1360-0443.2011.03402.x> [↑](#endnote-ref-71)
72. Tobacco Product Standard for Nicotine Yield of Cigarettes and Certain Other Combusted Tobacco Products, 90 FR 5032 5032 (2025). <https://www.federalregister.gov/d/2025-00397> [↑](#endnote-ref-72)
73. WHO Study Group on Tobacco Product Regulation (TobReg). (2015). *Advisory note: Global nicotine reduction strategy*. <https://www.who.int/publications/i/item/advisory-note-global-nicotine-reduction-strategy-who-study-group-on-tobacco-product-regulation> [↑](#endnote-ref-73)
74. European Union. (2014, April 3). *Tobacco Products Directive 2014/40/EU*. EUR-Lex. <https://eur-lex.europa.eu/eli/dir/2014/40/oj/eng> [↑](#endnote-ref-74)
75. Institute for Global Tobacco Control. *Product regulation | Global Tobacco Control*. Johns Hopkins School of Global Public Health. Retrieved 11 May 2025, from <https://www.globaltobaccocontrol.org/en/policy-scan/e-cigarettes/product-regulation> [↑](#endnote-ref-75)
76. Dawkins, L., Cox, S., Goniewicz, M., McRobbie, H., Kimber, C., Doig, M., & Kośmider, L. (2018). ‘Real-world’ compensatory behaviour with low nicotine concentration e-liquid: Subjective effects and nicotine, acrolein and formaldehyde exposure. *Addiction*, *113*(10), 1874–1882. <https://doi.org/10.1111/add.14271> [↑](#endnote-ref-76)
77. Kośmider, L., Kimber, C. F., Kurek, J., Corcoran, O., & Dawkins, L. E. (2018). Compensatory Puffing With Lower Nicotine Concentration E-liquids Increases Carbonyl Exposure in E-cigarette Aerosols. *Nicotine & Tobacco Research*, *20*(8), 998–1003. <https://doi.org/10.1093/ntr/ntx162> [↑](#endnote-ref-77)
78. Shihadeh, A., & Eissenberg, T. (2015). Electronic Cigarette Effectiveness and Abuse Liability: Predicting and Regulating Nicotine Flux. *Nicotine & Tobacco Research*, *17*(2), 158–162. <https://doi.org/10.1093/ntr/ntu175> [↑](#endnote-ref-78)
79. El-Hellani, A., Hanna, E., Sharma, M., Blohowiak, R., Joseph, P., Eid, T., Nadim, H., El-Hage, R., Salman, R., Karaoghlanian, N., Adeniji, A., Salam, S., Talih, F., Elbejjani, M., Breland, A., Eissenberg, T., Shihadeh, A., Baldassarri, S. R., & Talih, S. (2023). Nicotine flux as a powerful tool for regulating nicotine delivery from e-cigarettes: Protocol of two complimentary randomized crossover clinical trials. *PLOS ONE*, *18*(9), e0291786. <https://doi.org/10.1371/journal.pone.0291786> [↑](#endnote-ref-79)
80. Patev, A. J., Combs, M., Gaitan, N., Karaoghlanian, N., Lipato, T., Eissenberg, T., & Breland, A. (2024). Constraining electronic nicotine delivery systems (ENDS) nicotine dose by controlling nicotine flux at a limited puff duration. *Experimental and Clinical Psychopharmacology*, *32*(5), 604–614. <https://doi.org/10.1037/pha0000719> [↑](#endnote-ref-80)
81. Kolli, A. R., Veljkovic, E., Calvino-Martin, F., Esposito, M., Kuczaj, A. K., Koumal, O., Rose, J. E., & Peitsch, M. C. (2024). Nicotine flux and pharmacokinetics-based considerations for early assessment of nicotine delivery systems. *Drug and Alcohol Dependence Reports*, *11*, 100245. <https://doi.org/10.1016/j.dadr.2024.100245> [↑](#endnote-ref-81)
82. Russell, M. A. (1976). Low-tar medium-nicotine cigarettes: A new approach to safer smoking. *British Medical Journal*, *1*(6023), 1430–1433. [10.1136/bmj.1.6023.1430](https://doi.org/10.1136/bmj.1.6023.1430)  [↑](#endnote-ref-82)
83. Gottlieb, S., & Zeller, M. (2017) *A Nicotine-Focused Framework for Public Health* The New England Journal of Medicine; Massachusetts Medical Society. <https://doi.org/10.1056/NEJMp1707409> [↑](#endnote-ref-83)
84. Fisher, M. T., Tan-Torres, S. M., Gaworski, C. L., Black, R. A., & Sarkar, M. A. (2019). Smokeless tobacco mortality risks: An analysis of two contemporary nationally representative longitudinal mortality studies. *Harm Reduction Journal*, *16*, 27. <https://doi.org/10.1186/s12954-019-0294-6> [↑](#endnote-ref-84)
85. Rodu, B., & Plurphanswat, N. (2019). Mortality among male smokers and smokeless tobacco users in the USA. *Harm Reduction Journal*, *16*(1), 50. <https://doi.org/10.1186/s12954-019-0321-7> [↑](#endnote-ref-85)
86. Lee, P. N. (2011). Summary of the epidemiological evidence relating snus to health. Regulatory Toxicology and Pharmacology, 59(2), 197–214. [[link](https://doi.org/10.1016/j.yrtph.2010.12.002)] [↑](#endnote-ref-86)
87. Lee, P. N. (2013). Epidemiological evidence relating snus to health – an updated review based on recent publications. *Harm Reduction Journal*, *10*(1), 36. [[link](https://doi.org/10.1186/1477-7517-10-36)] [↑](#endnote-ref-87)
88. Food and Drug Administration (United States) *Modifications To Labeling of Nicotine Replacement Therapy Products for Over-the-Counter Human Use*. (2013, April 2). Federal Register. [78 FR 19718](https://www.federalregister.gov/documents/2013/04/02/2013-07528/modifications-to-labeling-of-nicotine-replacement-therapy-products-for-over-the-counter-human-use) [↑](#endnote-ref-88)
89. Murray, R. P., Connett, J. E., & Zapawa, L. M. (2009). Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. *Nicotine & Tobacco Research*, *11*(9), 1076–1082. <https://doi.org/10.1093/ntr/ntp104> [↑](#endnote-ref-89)
90. Fisher, M. T., Tan-Torres, S. M., Gaworski, C. L., Black, R. A., & Sarkar, M. A. (2019). Smokeless tobacco mortality risks: An analysis of two contemporary nationally representative longitudinal mortality studies. *Harm Reduction Journal*, *16*(1), 27. <https://doi.org/10.1186/s12954-019-0294-6> [↑](#endnote-ref-90)
91. Benowitz, N. L., & Burbank, A. D. (2016). Cardiovascular Toxicity of Nicotine: Implications for Electronic Cigarette Use. *Trends in Cardiovascular Medicine*, *26*(6), 515–523. <https://doi.org/10.1016/j.tcm.2016.03.001> [↑](#endnote-ref-91)
92. Hansson, J., Galanti, M. R., Hergens, M.-P., Fredlund, P., Ahlbom, A., Alfredsson, L., Bellocco, R., Eriksson, M., Hallqvist, J., Hedblad, B., Jansson, J.-H., Nilsson, P., Pedersen, N., Trolle Lagerros, Y., Östergren, P.-O., & Magnusson, C. (2012). Use of snus and acute myocardial infarction: Pooled analysis of eight prospective observational studies. *European Journal of Epidemiology*, *27*(10), 771–779. <https://doi.org/10.1007/s10654-012-9704-8> [↑](#endnote-ref-92)
93. Hansson, J., Galanti, M. R., Hergens, M.-P., Fredlund, P., Ahlbom, A., Alfredsson, L., Bellocco, R., Engström, G., Eriksson, M., Hallqvist, J., Hedblad, B., Jansson, J.-H., Pedersen, N. L., Trolle Lagerros, Y., Östergren, P.-O., & Magnusson, C. (2014). Snus (Swedish smokeless tobacco) use and risk of stroke: Pooled analyses of incidence and survival. *Journal of Internal Medicine*, *276*(1), 87–95. <https://doi.org/10.1111/joim.12219> [↑](#endnote-ref-93)
94. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. (2014). Nicotine (Chapter 5). In *The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General*. Centers for Disease Control and Prevention (US). <https://www.ncbi.nlm.nih.gov/books/NBK294308/> [↑](#endnote-ref-94)
95. Valen, H., Becher, R., Vist, G. E., Holme, J. A., Mdala, I., Elvsaas, I.-K. Ø., Alexander, J., Underland, V., Brinchmann, B. C., & Grimsrud, T. K. (2023). A systematic review of cancer risk among users of smokeless tobacco (Swedish snus) exclusively, compared with no use of tobacco. *International Journal of Cancer*, *153*(12), 1942–1953. <https://doi.org/10.1002/ijc.34643> [↑](#endnote-ref-95)
96. Warnakulasuriya, S., & Straif, K. (2018). Carcinogenicity of smokeless tobacco: Evidence from studies in humans & experimental animals. *The Indian Journal of Medical Research*, *148*(6), 681–686. <https://doi.org/10.4103/ijmr.IJMR_149_18> [↑](#endnote-ref-96)
97. Mo, R., Zhang, J., Chen, Y., & Ding, Y. (2022). Nicotine promotes chronic obstructive pulmonary disease via inducing pyroptosis activation in bronchial epithelial cells. *Molecular Medicine Reports*, *25*(3), 92. <https://doi.org/10.3892/mmr.2022.12608> [↑](#endnote-ref-97)
98. Tarasi, B., Cornuz, J., Clair, C., & Baud, D. (2022). Cigarette smoking during pregnancy and adverse perinatal outcomes: A cross-sectional study over 10 years. *BMC Public Health*, *22*(1), 2403. <https://doi.org/10.1186/s12889-022-14881-4> [↑](#endnote-ref-98)
99. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. (2014). *Reproductive Outcomes*. In The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Centers for Disease Control and Prevention (US). <https://www.ncbi.nlm.nih.gov/books/NBK294307/> [↑](#endnote-ref-99)
100. Pesola, F., Smith, K. M., Phillips-Waller, A., Przulj, D., Griffiths, C., Walton, R., McRobbie, H., Coleman, T., Lewis, S., Whitemore, R., Clark, M., Ussher, M., Sinclair, L., Seager, E., Cooper, S., Bauld, L., Naughton, F., Sasieni, P., Manyonda, I., & Hajek, P. (2024). Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial. *Addiction*, *119*(5), 875–884. <https://doi.org/10.1111/add.16422> [↑](#endnote-ref-100)
101. Ussher, M., Fleming, J., & Brose, L. (2024). Vaping during pregnancy: A systematic review of health outcomes. *BMC Pregnancy and Childbirth*, *24*(1), 435. <https://doi.org/10.1186/s12884-024-06633-6> [↑](#endnote-ref-101)
102. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. (2016). *Health Effects of E-Cigarette Use Among U.S. Youth and Young Adults*. In *E-Cigarette Use Among Youth and Young Adults: A Report of the Surgeon General [Internet]*. Centers for Disease Control and Prevention (US). <https://www.ncbi.nlm.nih.gov/books/NBK538688/> [↑](#endnote-ref-102)
103. Balfour, D. J. K., Benowitz, N. L., Colby, S. M., Hatsukami, D. K., Lando, H. A., Leischow, S. J., Lerman, C., Mermelstein, R. J., Niaura, R., Perkins, K. A., Pomerleau, O. F., Rigotti, N. A., Swan, G. E., Warner, K. E., & West, R. (2021). Balancing Consideration of the Risks and Benefits of E-Cigarettes. *American Journal of Public Health*, *111*(9), 1661–1672. <https://doi.org/10.2105/AJPH.2021.306416> [↑](#endnote-ref-103)
104. Corley, J., Gow, A. J., Starr, J. M., & Deary, I. J. (2012). Smoking, childhood IQ, and cognitive function in old age. *Journal of Psychosomatic Research*, *73*(2), 132–138. <https://doi.org/10.1016/j.jpsychores.2012.03.006> [↑](#endnote-ref-104)
105. Miller, A. P., Baranger, D. A. A., Paul, S. E., Garavan, H., Mackey, S., Tapert, S. F., LeBlanc, K. H., Agrawal, A., & Bogdan, R. (2024). Neuroanatomical Variability and Substance Use Initiation in Late Childhood and Early Adolescence. *JAMA Network Open*, *7*(12), e2452027. <https://doi.org/10.1001/jamanetworkopen.2024.52027> [↑](#endnote-ref-105)
106. Kardan, O., Weigard, A. S., Cope, L. M., Martz, M. M., Angstadt, M., McCurry, K. L., Michael, C., Hardee, J. E., Hyde, L. W., Sripada, C., & Heitzeg, M. M. (2024). Functional Brain Connectivity Predictors of Prospective Substance Use Initiation and Their Environmental Correlates. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging*. <https://doi.org/10.1016/j.bpsc.2024.10.002> [↑](#endnote-ref-106)
107. Newhouse, P., And, A. S., & Potter, A. (n.d.). Nicotine and Nicotinic Receptor Involvement in Neuropsychiatric Disorders. *Current Topics in Medicinal Chemistry*, *4*(3), 267–282. <https://doi.org/10.2174/1568026043451401> [↑](#endnote-ref-107)
108. Mihailescu, S., & Drucker-Colı́n, R. (2000). Nicotine, Brain Nicotinic Receptors, and Neuropsychiatric Disorders. *Archives of Medical Research*, *31*(2), 131–144. <https://doi.org/10.1016/S0188-4409(99)00087-9> [↑](#endnote-ref-108)
109. Lechner, W. V., Janssen, T., Kahler, C. W., Audrain-McGovern, J., & Leventhal, A. M. (2017). Bi-directional associations of electronic and combustible cigarette use onset patterns with depressive symptoms in adolescents. *Preventive Medicine*, *96*, 73–78. <https://doi.org/10.1016/j.ypmed.2016.12.034> [↑](#endnote-ref-109)
110. Kutlu, M. G., Parikh, V., & Gould, T. J. (2015). Chapter Seven—Nicotine Addiction and Psychiatric Disorders. In M. De Biasi (Ed.), *International Review of Neurobiology* (Vol. 124, pp. 171–208). Academic Press. <https://doi.org/10.1016/bs.irn.2015.08.004> [↑](#endnote-ref-110)
111. Fluharty, M., Taylor, A. E., Grabski, M., & Munafò, M. R. (2017). The Association of Cigarette Smoking With Depression and Anxiety: A Systematic Review. *Nicotine & Tobacco Research*, *19*(1), 3–13. <https://doi.org/10.1093/ntr/ntw140> [↑](#endnote-ref-111)
112. Farooqui, M., Shoaib, S., Afaq, H., Quadri, S., Zaina, F., Baig, A., Liaquat, A., Sarwar, Z., Zafar, A., & Younus, S. (2023). Bidirectionality of smoking and depression in adolescents: A systematic review. *Trends in Psychiatry and Psychotherapy*, *45*, e20210429. <https://doi.org/10.47626/2237-6089-2021-0429> [↑](#endnote-ref-112)
113. Weiger, C., Moran, M. B., Kennedy, R. D., Limaye, R., & Cohen, J. (2022). Beliefs and Characteristics Associated With Believing Nicotine Causes Cancer: A Descriptive Analysis to Inform Corrective Message Content and Priority Audiences. *Nicotine & Tobacco Research*, *24*(8), 1264–1272. <https://doi.org/10.1093/ntr/ntac060> [↑](#endnote-ref-113)
114. Gendall, P., Popova, L., Thrasher, J., & Hoek, J. (2024). Nicotine beliefs and perceptions of low nicotine labels and mitigating statements among people who do and do not smoke: A cross-sectional study from Aotearoa New Zealand. *Tobacco Control*, tc-2023-058353. <https://doi.org/10.1136/tc-2023-058353> [↑](#endnote-ref-114)
115. McNeill, A, Simonavičius, E, Brose, LS, Taylor, E, East, K, Zuikova, E, Calder, R and Robson, D (2022). Nicotine vaping in England: an evidence update including health risks and perceptions, September 2022. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities. <https://bit.ly/3Gj5NhV> [↑](#endnote-ref-115)
116. Steinberg, M. B., Bover Manderski, M. T., Wackowski, O. A., Singh, B., Strasser, A. A., & Delnevo, C. D. (2021). Nicotine Risk Misperception Among US Physicians. *Journal of General Internal Medicine*, *36*(12), 3888–3890. <https://doi.org/10.1007/s11606-020-06172-8> [↑](#endnote-ref-116)